Synova Announces Six-Month Data for Non-Invasive Fetal Monitor.MEDIA, Pa. -- Synova Pre-Natal Healthcare, Inc., a wholly-owned subsidiary of Synova Healthcare Group, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). : SNVH), has received product development results for its non-invasive fetal monitor Noun 1. fetal monitor - an electronic monitor that monitors fetal heartbeat and the mother's uterine contractions during childbirth electronic fetal monitor, electronic foetal monitor, foetal monitor . Synova is currently co-developing the device with BioPad Ltd., a research and development company based in Tel Aviv Tel Aviv (tĕl əvēv`), city (1994 pop. 355,200), W central Israel, on the Mediterranean Sea. Oficially named Tel Aviv–Jaffa, it is Israel's commercial, financial, communications, and cultural center and the core of its largest , Israel. Research has been conducted in Israel over the past six months on 130 expectant mothers expectant mother n → futura madre f expectant mother expect n → werdende Mutter f expectant mother n , and the preliminary data that has emerged is on par with published data findings from other fetal monitors that are currently marketed and commonly used in hospital settings across the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. . The non-invasive fetal movement fetal movement Kicking Obstetrics The constellation of activity by the fetus in the uterus which, in healthy infants, averages 10/hr monitoring device and the technology underlying the device that Synova and BioPad Ltd. are developing differs from these other monitoring devices in that they are designed to provide "at-home" self-monitoring information for expectant mothers. The Synova device is also much smaller in design than other existing monitoring devices and fits within the palm of a woman's hand. Dr. Ron Spangler, Chief Scientific Officer of Synova Healthcare Group, Inc., said: "While we are in the early stage of product development, we believe that these initial data are encouraging and represent a positive signal for us to proceed with our product development plans." The clinical program is ongoing in Israel, and it is planned that pivotal trials will be initiated in the United States during the second quarter of 2007. About Synova Healthcare Group, Inc. Synova Healthcare Group, Inc., through its subsidiaries Synova Healthcare, Inc. and Synova Pre-Natal Healthcare, Inc., is focused on the development, distribution, marketing and sale of non-invasive medical diagnostic tests that allow consumers and healthcare professionals to rapidly and accurately diagnose and monitor the onset of certain medical conditions See carpal tunnel syndrome, computer vision syndrome, dry eyes and deep vein thrombosis. . The Company's efforts are currently concentrated in the women's healthcare sector. Its goal is to supplant sup·plant tr.v. sup·plant·ed, sup·plant·ing, sup·plants 1. To usurp the place of, especially through intrigue or underhanded tactics. 2. traditional, more invasive, and costly diagnostic testing Diagnostic testing Testing performed to determine if someone is affected with a particular disease. Mentioned in: Von Willebrand Disease techniques, such as blood or serum assays, by offering rapid, non-invasive test alternatives. The Company's products afford consumers discreet use from home, and allow clinicians to offer streamlined healthcare services by providing rapid and accurate test results from within their offices. For further information, please visit the company's website at www.synovahealthcare.com. This Press Release may contain certain forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. The Company has tried, whenever possible, to identify these forward-looking statements using words such as "anticipates", "believes", "estimates", "expects", "plans", "intends", "potential" and similar expressions. These statements reflect the Company's current beliefs and are based upon information currently available to it. Accordingly, such forward-looking statements involve known and unknown risks, uncertainties and other factors which could cause the Company's actual results, performance or achievements to differ materially from those expressed in or implied by such statements. Such risk factors are discussed in the Company's Registration Statement on Form SB-2 (File No. 333-123498), as amended, as declared effective by the Securities and Exchange Commission on May 22, 2006, as well as in other periodic reports and filings with the Commission. There can be no assurance that such factors will not affect the accuracy of such forward-looking statements. The Company undertakes no obligation to update or advise in the event of any change, addition or alteration to the information set forth in this Press Release including such forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy; nor will there be any sale of securities of Synova Healthcare Group, Inc. in any state where such offer, solicitation or sale would be unlawful before registration or qualification under the securities laws of those states. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion